|Other Names||Bcl-2-interacting killer, Apoptosis inducer NBK, BIP1, BP4, BIK, NBK|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1319a was selected from the region of human Bik BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Accelerates programmed cell death. Association to the apoptosis repressors Bcl-X(L), BHRF1, Bcl-2 or its adenovirus homolog E1B 19k protein suppresses this death-promoting activity. Does not interact with BAX.|
|Cellular Location||Endomembrane system; Single-pass membrane protein. Mitochondrion membrane; Single-pass membrane protein. Note=Around the nuclear envelope, and in cytoplasmic membranes|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Bik protein is known to interact with cellular and viral survival-promoting proteins, such as BCL2 and the Epstein-Barr virus in order to enhance programmed cell death. Because its activity is suppressed in the presence of survival-promoting proteins, this protein is suggested as a likely target for antiapoptotic proteins. This protein shares a critical BH3 domain with other death-promoting proteins, BAX and BAK.
Arena, V., et al., Genes Chromosomes Cancer 38(1):91-96 (2003).Gillissen, B., et al., EMBO J. 22(14):3580-3590 (2003).Germain, M., et al., J. Biol. Chem. 277(20):18053-18060 (2002).Zou, Y., et al., Cancer Res. 62(1):8-12 (2002).Castells, A., et al., Gastroenterology 117(4):831-837 (1999).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.